| Loss Of Function Variant | Q27907094 |
| gene variant | Q28381983 |
| P3433 | biological variant of | BRCA1 | Q227339 |
| P1057 | chromosome | human chromosome 17 | Q220677 |
| P645 | genomic end | 41277500 | |
| P644 | genomic start | 41197646 | |
| P3355 | negative therapeutic predictor for | olaparib | Q7083106 |
| P3358 | positive prognostic predictor for | ovarian cancer | Q172341 |
| surface epithelial-stromal tumor | Q7645976 | ||
| P3354 | positive therapeutic predictor for | cediranib / olaparib combination therapy | Q44843714 |
| cisplatin | Q412415 | ||
| carboplatin | Q415588 | ||
| oxaliplatin | Q422327 | ||
| olaparib | Q7083106 | ||
| rucaparib | Q7376558 |
| Q34500480 | "My funky genetics": BRCA1/2 mutation carriers' understanding of genetic inheritance and reproductive merger in the context of new reprogenetic technologies |
| Q47204110 | "Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation |
| Q51788159 | 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24. |
| Q59264962 | 331TiPOLYMPIA, NEO-OLYMPIA AND OLYMPIAD: RANDOMIZED PHASE III TRIALS OF OLAPARIB IN PATIENTS (PTS) WITH BREAST CANCER (BC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM) |
| Q80527712 | 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily) |
| Q104758251 | BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target |
| Q48004215 | A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing |
| Q34122140 | A BRCA1 mutation in Native North American families |
| Q40019311 | A BRCA1 mutation is not associated with increased indicators of oxidative stress |
| Q42566648 | A BRCA1 nonsense mutation causes exon skipping |
| Q33948754 | A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival |
| Q63966376 | A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography |
| Q79089791 | A Biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A→C is a mutation |
| Q47897282 | A Finnish BRCA1 exon 12 4216-2nt A to G splice acceptor site mutation causes aberrant splicing and frameshift, leading to protein truncation |
| Q46833379 | A Founder Mutation of the BRCA1-Gene in Western Sweden |
| Q55425427 | A Germline Mutation in the BRCA1 3’UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population |
| Q36108172 | A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet |
| Q51091555 | A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. |
| Q34503833 | A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State |
| Q51475246 | A Nano-Biosensor for the Detection of 185delAG Mutation in BRCA1 Gene, Leading to Breast Cancer. |
| Q89493352 | A Novel BRCA1 Gene Mutation Detected With Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report |
| Q42366737 | A Novel Germline Mutation in BRCA1 Causes Exon 20 Skipping in a Korean Family with a History of Breast Cancer |
| Q91920031 | A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer |
| Q37602441 | A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype |
| Q91257973 | A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2 |
| Q88640343 | A Trans-Feminine Youth with a BRCA1 Mutation: Case Study |
| Q53925507 | A characterization of genetic variants in BRCA1 intron 8 identifies a mutation and a polymorphism. |
| Q24803679 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment |
| Q42590677 | A common BRCA1 mutation in Norwegian breast and ovarian cancer families? |
| Q53638062 | A common BRCA1 mutation in the Ashkenazim. |
| Q46578094 | A common Greenlandic Inuit BRCA1 RING domain founder mutation |
| Q41524956 | A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories |
| Q78237713 | A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC |
| Q34233873 | A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers. |
| Q84489938 | A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma |
| Q36138088 | A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer |
| Q38459569 | A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer |
| Q48357400 | A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another. |
| Q33764182 | A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer |
| Q53121377 | A high frequent BRCA1 founder mutation identified in the Greenlandic population. |
| Q80444290 | A high-throughput mutation detection method based on heteroduplex analysis using graft copolymer matrixes: application to Brca1 and Brca2 analysis |
| Q33942332 | A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q50060457 | A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1. |
| Q90360761 | A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine |
| Q33202841 | A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone |
| Q44492096 | A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer |
| Q80793740 | A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency |
| Q73734753 | A new BRCA1 germline mutation (E879X) in a Malaysian breast cancer patient of Chinese descent |
| Q77626786 | A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer |
| Q37672666 | A new case of "de novo" BRCA1 mutation in a patient with early-onset breast cancer |
| Q60684271 | A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer |
| Q73444832 | A new mutation in the BRCA1 gene (g.5196-5201del6, 5195-5202ins12), a 6 bp deletion replaced by the duplication of a 12 bp adjacent upstream intronic sequence |
| Q58704303 | A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report |
| Q35445946 | A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO |
| Q51132318 | A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening. |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q93057904 | A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents |
| Q80712107 | A novel BRCA1 mutation in a Spanish patient with ovarian cancer |
| Q27852587 | A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report |
| Q50774570 | A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. |
| Q30471451 | A novel BRCA1 mutation in an identical twin pair with similar clinical histories |
| Q35000825 | A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. |
| Q57173171 | A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes |
| Q36126841 | A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation |
| Q53008609 | A novel mutation in the BRCA1 gene in a German early-onset breast cancer family. |
| Q42539498 | A novel rapid and sensitive BRCA1/2 mutation detection method based on pooled DGGE and targeted sequencing. |
| Q47762116 | A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing. |
| Q27302763 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An |
| Q37004562 | A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers |
| Q37164443 | A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing |
| Q73160634 | A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example |
| Q34097351 | A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers |
| Q74459364 | A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers |
| Q48074726 | A somatic BRCA1 mutation in an ovarian tumour |
| Q40787469 | A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. |
| Q47818883 | A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. |
| Q79652344 | A survey of preventive measures among BRCA1 mutation carriers from Poland |
| Q35223166 | A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population |
| Q52133539 | A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. |
| Q44034270 | A unique BRCA1 mutation identified in Mongolia |
| Q83394196 | AIB1 polymorphisms with breast cancer susceptibility: a pooled analysis of variation in BRCA1/2 mutation carriers and non-carriers |
| Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
| Q79843966 | AURKA and breast cancer in BRCA1/2 mutation carriers |
| Q91043183 | Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study |
| Q42457867 | Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers |
| Q36114941 | Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer |
| Q33918764 | Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers |
| Q37356519 | Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier |
| Q83586111 | Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics |
| Q57754722 | Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan |
| Q40215732 | Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families |
| Q63378104 | Abstract 5598: Germline TP53 mutation in very early onset breast cancer patients without BRCA1 and BRCA2 mutation in Brazilian population |
| Q91958271 | Accuracy in risk understanding among BRCA1/2-mutation carriers |
| Q38437593 | Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. |
| Q35823504 | Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort |
| Q44171056 | Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients |
| Q90644812 | Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel |
| Q27324685 | Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives |
| Q52660676 | Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. |
| Q43613838 | Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom |
| Q53104688 | Added value of family history in counseling about risk of BRCA1/2 mutation in early-onset epithelial ovarian cancer. |
| Q35219159 | Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer |
| Q36210166 | Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. |
| Q30430808 | Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer |
| Q73420934 | Adrenal tumors in BRCA1/BRCA2 mutation carriers |
| Q84251514 | Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers |
| Q101467224 | Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors |
| Q57266698 | Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q88723598 | Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q59238426 | Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q88791860 | Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation |
| Q90905912 | Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers |
| Q91618412 | Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium |
| Q37129674 | Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers |
| Q57697514 | Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer |
| Q44762939 | Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation |
| Q51434979 | Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN). |
| Q34584841 | Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. |
| Q38622610 | Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer |
| Q43218212 | An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? |
| Q37676233 | An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity |
| Q46146264 | An audit of treatment focussed BRCA1/2 mutation testing at an integrated Familial Cancer Clinic |
| Q36882665 | An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers |
| Q36292792 | An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews |
| Q90273845 | An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers |
| Q34623703 | An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) |
| Q33901361 | An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers |
| Q42511786 | Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. |
| Q37097543 | Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer |
| Q89896922 | Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique |
| Q34480599 | Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource |
| Q78439258 | Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype |
| Q35633057 | Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis |
| Q57266543 | Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers |
| Q44400604 | Anticipatory loss and early mastectomy for young female BRCA1/2 mutation carriers |
| Q46029695 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. |
| Q39699496 | Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers |
| Q36590731 | Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent |
| Q91014265 | Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? |
| Q64018986 | Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer |
| Q42763529 | Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic? |
| Q48499810 | Are we ready for online tools in decision making for BRCA1/2 mutation carriers? |
| Q37209488 | Aromatase expression is increased in BRCA1 mutation carriers |
| Q82969885 | Aromatase, CYP1B1 and fatty acid synthase expression in breast tumors of BRCA1 mutation carriers |
| Q51544762 | Array-based mutation detection of BRCA1 using direct probe/target hybridization. |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q57937919 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival |
| Q91524389 | Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers |
| Q37046405 | Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer |
| Q64983153 | Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer. |
| Q64075313 | Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients |
| Q74528270 | Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer |
| Q91837173 | Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study |
| Q102331002 | Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers |
| Q38630567 | Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations |
| Q64090740 | Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q33943829 | Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q45341994 | Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers |
| Q93182845 | Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction |
| Q36444546 | Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier |
| Q34135443 | Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality |
| Q46121002 | Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q54548510 | Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler. |
| Q52373876 | Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. |
| Q40521165 | Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland |
| Q73747458 | Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation |
| Q43076239 | Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands |
| Q61970278 | Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers |
| Q73688320 | Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation |
| Q35921496 | Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation |
| Q42477044 | BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer |
| Q27002334 | BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African |
| Q36017531 | BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells |
| Q73171101 | BRCA1 185delAG mutation in a non-Ashkenazi Jewish woman with early-onset breast and ovarian cancer |
| Q47226272 | BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells |
| Q80871264 | BRCA1 2080insA mutation in familial breast cancer |
| Q33722598 | BRCA1 4153delA founder mutation in Russian ovarian cancer patients |
| Q53066394 | BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients. |
| Q36431727 | BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland |
| Q50618962 | BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer. |
| Q98974393 | BRCA1 Gene Exon11 Mutation in 50 Cases with Breast Cancer |
| Q35978230 | BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia |
| Q78002622 | BRCA1 IVS16+6T-->C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site |
| Q47812821 | BRCA1 IVS2-2delA: a deleterious mutation in a family of Asian descent |
| Q55645204 | BRCA1 Mutation Analysis in 27 Cypriot Families with High Risk of Hereditary Breast and Ovarian Cancer. |
| Q45780346 | BRCA1 Mutation Analysis in a Portuguese Population with Early-Onset Breast and/or Ovarian Cancer. |
| Q94305238 | BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells |
| Q55461779 | BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. |
| Q60499703 | BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials |
| Q58093836 | BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance |
| Q58696749 | BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance |
| Q36076772 | BRCA1 Mutation: A Predictive Marker for Radiation Therapy? |
| Q84814806 | BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels |
| Q44312982 | BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype |
| Q91330811 | BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report |
| Q91142403 | BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM) |
| Q34513583 | BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer |
| Q72996871 | BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC) |
| Q57728286 | BRCA1 and BRCA2 genes mutation analysis in patients with a family history of breast and ovarian cancer |
| Q81415321 | BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model |
| Q83946484 | BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models |
| Q35006713 | BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation |
| Q33304489 | BRCA1 and BRCA2 germline mutation analysis in the Indonesian population |
| Q36694756 | BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families |
| Q38108675 | BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries |
| Q36115744 | BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1 |
| Q33679850 | BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients |
| Q34188184 | BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland |
| Q34145544 | BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer |
| Q78545240 | BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico |
| Q33890070 | BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials |
| Q37416050 | BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research |
| Q34571646 | BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. |
| Q57903126 | BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic |
| Q34480647 | BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families |
| Q40350775 | BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. |
| Q45906306 | BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. |
| Q40321627 | BRCA1 and BRCA2 mutation screening using SmartCycler II high-resolution melt curve analysis |
| Q48534893 | BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. |
| Q35437468 | BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. |
| Q44288645 | BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. |
| Q36203178 | BRCA1 and BRCA2 mutation testing in Cyprus; a population based study |
| Q87149893 | BRCA1 and BRCA2 mutation type associated with cancer risk |
| Q36335840 | BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers |
| Q64284450 | BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers |
| Q53341743 | BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. |
| Q40257922 | BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation |
| Q76345671 | BRCA1 c.2845insA is a founder mutation in Singaporean Malay women with early onset breast/ovarian cancer |
| Q35440846 | BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer |
| Q43043803 | BRCA1 c.4987-3C>G is a pathogenic mutation. |
| Q92762217 | BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients |
| Q64388133 | BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters |
| Q78167037 | BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer |
| Q45176967 | BRCA1 gene mutation in thymic malignant melanoma |
| Q36315223 | BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses |
| Q59530329 | BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses |
| Q35226053 | BRCA1 germline mutation and glioblastoma development: report of cases |
| Q42513661 | BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer |
| Q57385853 | BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary |
| Q40150460 | BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination |
| Q90824237 | BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells |
| Q59312570 | BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families |
| Q46945553 | BRCA1 mutation analysis in breast and ovarian cancer families from Greece. |
| Q44909070 | BRCA1 mutation analysis in breast/ovarian cancer families from Greece |
| Q40333192 | BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants |
| Q43472560 | BRCA1 mutation and neuronal migration defect: implications for chemoprevention |
| Q43073200 | BRCA1 mutation and neuronal migration defect: implications for chemoprevention. |
| Q38613013 | BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. |
| Q64915704 | BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival. |
| Q59288480 | BRCA1 mutation in the Triple- Negative Breast Cancer Group |
| Q91471049 | BRCA1 mutation influences progesterone response in human benign mammary organoids |
| Q78657550 | BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system |
| Q53001101 | BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas. |
| Q49917693 | BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. |
| Q73351867 | BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening |
| Q71960588 | BRCA1 mutation testing: controversies and challenges |
| Q53370485 | BRCA1 mutation update and analysis. |
| Q46459960 | BRCA1 mutation, leptin and estrogen levels in breast cancer patients |
| Q46738371 | BRCA1 mutation- oncological treatment- reconstructive surgery of the breast- pregnancy: diagnostic and therapeutic procedures in a 28 year old patient diagnosed with a tumor in the left breast with a BRCA1 mutation |
| Q54409850 | BRCA1 mutations and colorectal cancer in Poland. |
| Q34321175 | BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families |
| Q33618422 | BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. |
| Q21195223 | BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype |
| Q33869633 | BRCA1 reversion mutation acquired after treatment identified by liquid biopsy |
| Q92747658 | BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations |
| Q38538274 | BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review |
| Q52715784 | BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. |
| Q33930051 | BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation |
| Q51745892 | BRCA1/2 mutation analysis in male breast cancer families from North West England. |
| Q38188182 | BRCA1/2 mutation carriers are potentially at higher cardiovascular risk |
| Q80497070 | BRCA1/2 mutation carriers: living with susceptibility |
| Q24805707 | BRCA1/2 mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancer |
| Q34773464 | BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families |
| Q92487458 | BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling |
| Q59689002 | BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases |
| Q85363448 | BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer |
| Q37157563 | BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy |
| Q90387292 | BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients |
| Q50137552 | BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. |
| Q57694517 | BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial |
| Q57419722 | BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy |
| Q48257542 | BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. |
| Q42452703 | Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers |
| Q36643102 | Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q38175815 | Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers |
| Q28085448 | Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers |
| Q39699130 | Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q40592257 | Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q47189470 | Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group |
| Q51715408 | Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. |
| Q79214311 | Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing |
| Q36384041 | Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers |
| Q41161920 | Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis |
| Q47418222 | Body weight and risk of breast cancer in BRCA1/2 mutation carriers |
| Q92196932 | Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status |
| Q57892661 | Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers |
| Q102386033 | Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program |
| Q86581656 | Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers |
| Q57250721 | Breast Cancer Risk in Ashkenazi BRCA1/2 Mutation Carriers: Effects of Reproductive History |
| Q40258706 | Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. |
| Q92597446 | Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer |
| Q51051671 | Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. |
| Q35643852 | Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. |
| Q35925255 | Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers |
| Q35263462 | Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2. |
| Q44941961 | Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome |
| Q51840854 | Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene. |
| Q34873841 | Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec |
| Q34084471 | Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation |
| Q51009185 | Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study. |
| Q40273462 | Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers |
| Q90706926 | Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation |
| Q72406546 | Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21 |
| Q43624639 | Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? |
| Q57143294 | Breast cancer prevention in BRCA1/2 mutation carriers: a qualitative review |
| Q35039870 | Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. |
| Q78198665 | Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers |
| Q41195564 | Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction |
| Q34718829 | Breast cancer risk among male BRCA1 and BRCA2 mutation carriers |
| Q53265333 | Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. |
| Q26823062 | Breast cancer risk in BRCA1 mutation carriers: insight from mouse models |
| Q91972558 | Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance |
| Q73400704 | Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland |
| Q46520947 | Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. |
| Q37081117 | Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation |
| Q83528942 | Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy |
| Q51114234 | Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. |
| Q38389226 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. |
| Q82037707 | Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution |
| Q91415410 | Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough? |
| Q34266272 | Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer. |
| Q43639185 | Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers |
| Q36538605 | Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. |
| Q43670876 | Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis |
| Q86987444 | Breast-conserving Therapy and the Risk of Second Primaries in BRCA1/2 Mutation Carriers |
| Q84337229 | Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? |
| Q98291245 | Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population |
| Q53287209 | Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. |
| Q24598482 | Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q100430759 | Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation |
| Q82723087 | CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer |
| Q48219124 | CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort |
| Q81824595 | CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12 |
| Q44512055 | CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families |
| Q82697794 | Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation? |
| Q43509792 | Can self-esteem, mastery and perceived stigma predict long-term adjustment in women carrying a BRCA1/2-mutation? Evidence from a multi-center study |
| Q34527264 | Cancer Incidence in BRCA1 mutation carriers |
| Q37091106 | Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. |
| Q57903119 | Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program |
| Q24802534 | Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status |
| Q43613940 | Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation |
| Q51726517 | Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. |
| Q44390637 | Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers |
| Q36610578 | Cancer risks among BRCA1 and BRCA2 mutation carriers |
| Q80322439 | Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation |
| Q44946113 | Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. |
| Q41195724 | Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers |
| Q36930042 | Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status |
| Q35219186 | Cancer worry among Norwegian male BRCA1/2 mutation carriers |
| Q39050188 | Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37526389 | Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. |
| Q40124999 | Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines |
| Q52677836 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. |
| Q30248813 | Cardiovascular risk of BRCA1/2 mutation carriers: A review |
| Q50628157 | Cascade screening in BRCA1/2 mutation carriers. |
| Q24813705 | Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q61917183 | Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers |
| Q30836057 | Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry |
| Q46107528 | Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries |
| Q73333633 | Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation |
| Q35565644 | Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women |
| Q43124708 | Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging |
| Q39461339 | Characterization of BARD1 targeting and dynamics at the centrosome: the role of CRM1, BRCA1 and the Q564H mutation. |
| Q41017582 | Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. |
| Q40662259 | Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. |
| Q35091400 | Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. |
| Q43417392 | Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg). |
| Q91818139 | Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy |
| Q39401450 | Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery |
| Q60936278 | Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment |
| Q34074418 | Chemoprevention options for BRCA1 and BRCA2 mutation carriers. |
| Q64119722 | Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients |
| Q37249356 | Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation |
| Q53157575 | Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers. |
| Q44378636 | Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. |
| Q54611493 | Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. |
| Q91838401 | Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study |
| Q37638732 | Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers |
| Q86002845 | Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers |
| Q34738030 | Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling |
| Q35687632 | Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review |
| Q92209176 | Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients |
| Q91104458 | Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study |
| Q57481433 | Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review |
| Q46944601 | Clinical and pathological characteristics in patients with BRCA1/2-mutation associated with breast cancer (BC) with a long clinical follow-up. |
| Q81895458 | Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain |
| Q33184753 | Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation |
| Q36446316 | Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients |
| Q34568554 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q82241176 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q36754871 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation |
| Q55711192 | Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. |
| Q34313361 | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
| Q33863531 | Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers |
| Q38306900 | Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review |
| Q91206331 | Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients |
| Q74201993 | Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one single family |
| Q75246661 | Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan |
| Q62937866 | Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q90507121 | Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers |
| Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
| Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
| Q36738628 | Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers |
| Q40633758 | Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer |
| Q51280306 | Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. |
| Q33584055 | Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients |
| Q43087346 | Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening |
| Q36791430 | Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California |
| Q33858717 | Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group |
| Q37116781 | Comparison of whole genome amplification and nested-PCR methods for preimplantation genetic diagnosis for BRCA1 gene mutation on unfertilized oocytes-a pilot study |
| Q52689244 | Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. |
| Q46845832 | Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. |
| Q37363251 | Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway |
| Q88995149 | Complex Medical Decision-Making for a Trans-Feminine Youth with a BRCA1 Mutation |
| Q42870176 | Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation |
| Q37778781 | Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. |
| Q89443743 | Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas |
| Q77523705 | Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population |
| Q34613122 | Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil |
| Q64941413 | Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women. |
| Q53500717 | Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation. |
| Q48608272 | Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. |
| Q89966956 | Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer |
| Q34503454 | Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. |
| Q35771756 | Conservative management of breast cancer in BRCA1/2 mutation carriers |
| Q90481059 | Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results |
| Q74243267 | Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening |
| Q33646285 | Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer |
| Q30410984 | Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report |
| Q34548640 | Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q84786111 | Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side |
| Q84786183 | Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q89616949 | Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients |
| Q37577739 | Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). |
| Q64055786 | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
| Q36882035 | Contribution of BRCA1 germline mutation in patients with sporadic breast cancer. |
| Q84006257 | Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation |
| Q113241830 | Correction: When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans |
| Q57266812 | Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000 |
| Q49486272 | Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. |
| Q59808023 | Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
| Q104577883 | Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial |
| Q50091589 | Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. |
| Q51000641 | Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. |
| Q91138710 | Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer |
| Q34803360 | Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers |
| Q48526678 | Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. |
| Q36652732 | Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers |
| Q33679857 | Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers |
| Q79428793 | Cost-effectiveness of breast magnetic resonance imaging to screen BRCA1/2 mutation carriers |
| Q44317248 | Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation |
| Q33244418 | Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging |
| Q47246829 | Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers |
| Q47771873 | Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? |
| Q38281709 | Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. |
| Q36203244 | DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36610563 | DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers |
| Q38864434 | DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers |
| Q43218563 | De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation |
| Q77948967 | Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy |
| Q50694376 | Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy. |
| Q89942541 | Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling |
| Q85077696 | Defining variations in survival of BRCA1 and BRCA2 mutation carriers |
| Q37111145 | Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions |
| Q46418706 | Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas |
| Q113241836 | Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation |
| Q37055268 | Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing |
| Q84868019 | Designed hybridization properties of DNA-gold nanoparticle conjugates for the ultraselective detection of a single-base mutation in the breast cancer gene BRCA1 |
| Q51523812 | Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method. |
| Q53080410 | Detection of a novel mutation in exon 20 of the BRCA1 gene. |
| Q59274312 | Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations? |
| Q45078987 | Determination of a BRCA1 gene mutation in a family with hereditary breast cancer |
| Q91126843 | Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation |
| Q36918953 | Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation |
| Q38800545 | Development of a Tool to Guide Parents Carrying a BRCA1/2 Mutation Share Genetic Results with Underage Children |
| Q44967435 | Development of breast cancer in a 21-year-old childhood Wilms' tumor survivor with a BRCA1 2634delC mutation |
| Q38297766 | Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature |
| Q33588213 | Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers |
| Q47999441 | Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner |
| Q47147531 | Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. |
| Q53441907 | Dideoxy fingerprinting assay for BRCA1 mutation analysis. |
| Q88411935 | Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers |
| Q51187701 | Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. |
| Q59312617 | Differences in phenotypic expression of a new BRCA1 mutation in identical twins |
| Q58813401 | Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation |
| Q91125266 | Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer |
| Q73025637 | Direct genomic multiplex PCR for BRCA1 and application to mutation detection by single-strand conformation and heteroduplex analysis |
| Q34038720 | Disclosure of Positive BRCA1/2-Mutation Status in Young Couples: The Journey From Uncertainty to Bonding Through Partner Support |
| Q88024388 | Displaced granulosa cells within the ovarian stroma in a BRCA1 mutation carrier |
| Q77357615 | Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study |
| Q91473174 | Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study |
| Q43642380 | Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer |
| Q40689845 | Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? |
| Q40507697 | Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity? |
| Q44250031 | Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation? |
| Q34125241 | Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? |
| Q82209444 | Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? |
| Q41221895 | Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? |
| Q35758939 | Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population |
| Q91777956 | Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report |
| Q52193951 | Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. |
| Q94594733 | Double mutation of APC and BRCA1 in an Italian family |
| Q53675873 | Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. |
| Q34039438 | Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q47243157 | ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers |
| Q35749439 | Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study |
| Q35237240 | Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1 |
| Q97689503 | Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems |
| Q37727064 | Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis |
| Q38548370 | Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers |
| Q33722531 | Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers |
| Q57266745 | Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group |
| Q51798328 | Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. |
| Q48374179 | Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial. |
| Q47614988 | Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers |
| Q34874938 | Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study |
| Q34435034 | Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers |
| Q38775675 | Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review |
| Q33181647 | Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk |
| Q92348228 | Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review |
| Q36807594 | Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review |
| Q92108045 | Effects of 3300 del A-1061 Ter BRCA1 frameshift mutation and calcium propionate on oxidative stress and breast carcinogenesis |
| Q35679122 | Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers |
| Q58595494 | Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation |
| Q114672646 | Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study |
| Q37138925 | Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial |
| Q73293986 | Effects of spouses on distress experienced by BRCA1 mutation carriers over time |
| Q37193459 | Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy |
| Q47939487 | Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers |
| Q77137456 | Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers |
| Q38127164 | Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study |
| Q33853726 | Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection |
| Q44414782 | Electroretinographic Changes in Eyes of Patients with BRCA1 Gene Mutation |
| Q57694442 | Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers |
| Q45923424 | Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. |
| Q34994680 | Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier |
| Q46547323 | Elucidation of the transmission of a novel mutation in BRCA1 (1125delCT) in a family with multiple cases of breast cancer. |
| Q99352021 | Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects |
| Q44498721 | Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers |
| Q37781001 | Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2. |
| Q44673255 | Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics |
| Q38609944 | Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation |
| Q92284095 | Erratum to "Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study" by Lieske H Schrijver et al |
| Q40890600 | Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation |
| Q47386686 | Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach |
| Q38974510 | Estimation of the RNU2 macrosatellite mutation rate by BRCA1 mutation tracing |
| Q92377028 | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
| Q33892942 | Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features |
| Q86554647 | Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consorti |
| Q37004792 | Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q50072452 | Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection. |
| Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
| Q34806825 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. |
| Q43218569 | Evidence for a BRCA1 founder mutation in families of West African ancestry |
| Q46160823 | Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry |
| Q60661751 | Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation |
| Q24649433 | Evidence of a founder BRCA1 mutation in Scotland |
| Q34084450 | Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. |
| Q53392865 | Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. |
| Q98945894 | Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review |
| Q90426509 | Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter? |
| Q37312028 | Experience of BRCA1/2 mutation-negative young women from families with hereditary breast and ovarian cancer: a qualitative study |
| Q39841291 | Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study |
| Q39452302 | Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future |
| Q89545164 | Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives |
| Q38976845 | Exploration of Male Attitudes on Partnerships and Sexuality with Female BRCA1/2 Mutation Carriers |
| Q34497601 | Exploring attitudes, beliefs, and communication preferences of Latino community members regarding BRCA1/2 mutation testing and preventive strategies. |
| Q46943673 | Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers |
| Q44233009 | Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen |
| Q53664165 | Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. |
| Q33327785 | Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers |
| Q43002662 | Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers. |
| Q43454654 | External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years |
| Q39383797 | Ex vivo retrieval and cryopreservation of oocytes from oophorectomized specimens for fertility preservation in a BRCA1 mutation carrier with ovarian cancer |
| Q50602048 | FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns. |
| Q35690548 | Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q59238470 | Fallopian tube cancer in a BRCA1 mutation carrier: Rapid development and failure of screening |
| Q53487694 | Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. |
| Q51090721 | Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. |
| Q51770580 | Familial effects of BRCA1 genetic mutation testing: changes in perceived family functioning. |
| Q42642919 | Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis |
| Q37110299 | Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation |
| Q39395789 | Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families |
| Q24655010 | Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations |
| Q27316521 | Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers |
| Q45963434 | Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1). |
| Q40508469 | Fertility intentions following testing for a BRCA1 gene mutation. |
| Q50577161 | Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. |
| Q91546130 | Film-Spotting chiral miniPEG-γPNA array for BRCA1 gene mutation detection |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q37108486 | First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene |
| Q37440121 | First case of invasive breast cancer following prophylactic bilateral skin sparing mastectomy in a BRCA1 mutation carrier |
| Q36546414 | First description of a sporadic breast cancer in a woman with BRCA1 germline mutation |
| Q34572133 | First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report |
| Q93067273 | Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers |
| Q91575301 | Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials |
| Q90858403 | Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study |
| Q81465978 | Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome |
| Q73692281 | Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore |
| Q54279806 | Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India. |
| Q46642006 | Frequency of 5382insC mutation of the BRCA1 gene |
| Q33853807 | Frequency of BRCA1 mutation 5382insC in German breast cancer patients. |
| Q59238271 | Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation |
| Q44255728 | Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer |
| Q71102445 | Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls |
| Q85253288 | Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations |
| Q36643587 | Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa |
| Q28260374 | Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin |
| Q24803349 | Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers |
| Q57390836 | G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history |
| Q48276305 | Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. |
| Q101452686 | Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues |
| Q38344861 | Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status |
| Q39911675 | Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. |
| Q57694666 | Genetic Testing for Women Previously Diagnosed with Breast/Ovarian Cancer: Examining the Impact of BRCA1 and BRCA2 Mutation Searching |
| Q37834134 | Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q88247117 | Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation |
| Q38287414 | Genetic testing and interpretive complexity: a BRCA1 gene mutation example. |
| Q54099249 | Genetic testing for BRCA1 mutation in the UK. |
| Q73210569 | Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing |
| Q98286256 | Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer? |
| Q33811527 | Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q84744697 | Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency |
| Q91582420 | Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer |
| Q34059765 | Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia |
| Q41835115 | Genotyping of frequent BRCA1/2 SNPs with unlabeled probes: a supplement to HRMCA mutation scanning, allowing the strong reduction of sequencing burden |
| Q89777468 | Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial |
| Q34141317 | Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed |
| Q70908338 | Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer |
| Q52906534 | Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. |
| Q42654026 | German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene |
| Q92786479 | Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib |
| Q91532180 | Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation |
| Q74595265 | Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families |
| Q81563570 | Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India |
| Q37619695 | Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. |
| Q89425978 | Germline BRCA1-associated protein 1 mutation presenting as BAP1 inactivated melanocytic nevi in a child of a father with fatal paraganglioma |
| Q30250240 | Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review |
| Q58325199 | Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families |
| Q73088192 | Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families |
| Q35114576 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer |
| Q92740799 | Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients |
| Q53461969 | Germline mutation of BRCA1 in Japanese breast cancer families. |
| Q42509342 | Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. |
| Q54457100 | Germline mutation screening of the Saethre-Chotzen-associated genes TWIST1 and FGFR3 in families with BRCA1/2-negative breast cancer. |
| Q47566263 | Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives |
| Q59791165 | Giant prolactinoma, germline BRCA1 mutation, and depression: a case report |
| Q36740618 | Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers |
| Q57728295 | Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients |
| Q61896335 | Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers |
| Q37611329 | HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases |
| Q44202163 | HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry |
| Q34586591 | HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers |
| Q46008556 | Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation. |
| Q33327591 | Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent |
| Q59238455 | Haplotype analysis of a BRCA1 : 185delAG mutation in a Chilean family supports its Ashkenazi origins |
| Q36543070 | Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations |
| Q100760577 | Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia |
| Q40674850 | Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation |
| Q46175390 | Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin |
| Q84211456 | Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals |
| Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
| Q95842872 | Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer |
| Q87103049 | Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation |
| Q57173042 | Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q92586752 | Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study |
| Q55194957 | Hereditary Breast Cancer in Latvia: Mutation Analysis of the BRCA1 Gene. |
| Q71257737 | Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation |
| Q31956444 | Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice |
| Q86824997 | Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation |
| Q73141885 | Hierarchical mutation screening protocol for the BRCA1 gene |
| Q110659441 | High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer |
| Q47833985 | High demoralization in a minority of oophorectomized BRCA1/2 mutation carriers influences quality of life. |
| Q41357330 | High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation. |
| Q46637931 | High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk |
| Q53448823 | High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. |
| Q46922759 | High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. |
| Q81587439 | High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland |
| Q42447874 | High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors |
| Q36474986 | High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing |
| Q46119470 | High prevalence of a BRCA1 gene founder mutation, 5083del19, in unselected breast–ovarian cancer patients from Southern Italy: genotype–phenotype correlations |
| Q82615881 | High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers |
| Q75191455 | High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis |
| Q34031941 | Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds |
| Q24796660 | Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q47185834 | Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. |
| Q40798697 | Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation |
| Q88516911 | Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers |
| Q93492613 | Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2) |
| Q47635634 | Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study |
| Q93191235 | Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis |
| Q53354746 | Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. |
| Q82495324 | Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers |
| Q38272017 | Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects |
| Q48029824 | Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers |
| Q99553437 | Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety |
| Q36916140 | Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers |
| Q38164226 | Hormone therapy in oophorectomized BRCA1/2 mutation carriers. |
| Q57634473 | How Reliable Are BRCA1/2 Mutation Estimates? |
| Q80352327 | How reliable are BRCA1/2 mutation estimates? |
| Q63359213 | Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation |
| Q47559910 | Identification as a Mutation Carrier and Effects on Life According to Experiences of Finnish Male BRCA1/2 Mutation Carriers. |
| Q87974680 | Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy |
| Q73804665 | Identification of BRCA1 germline mutation, 797delAA, in a Japanese breast-ovarian cancer patient |
| Q91411781 | Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer |
| Q39006425 | Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls |
| Q57053903 | Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer |
| Q39375023 | Identification of a founder BRCA1 mutation in the Moroccan population. |
| Q57363991 | Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for br |
| Q91051564 | Identification of a novel breast cancer-causing mutation in the BRCA1 gene by targeted next generation sequencing: A case report |
| Q57419183 | Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients |
| Q47842187 | Identification of a possible somatic BRCA1 mutation affecting translation efficiency in an early-onset sporadic breast cancer patient |
| Q33775466 | Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers |
| Q73649502 | Identification of a recurrent BRCA1 mutation in German breast-cancer and/or ovarian-cancer families |
| Q38501477 | Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers |
| Q46738244 | Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation |
| Q37693410 | Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort |
| Q59312609 | Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population |
| Q84549013 | Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan |
| Q92396258 | Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation |
| Q44594038 | Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. |
| Q75294706 | Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family |
| Q39534656 | Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? |
| Q38677974 | Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q55717426 | Impact of BRCA1 mutation on survival after early onset breast cancer. |
| Q39065794 | Impact of BRCA1/2 mutation on young women's 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort). |
| Q77476124 | Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample |
| Q35050959 | Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers |
| Q33633402 | Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation |
| Q38814032 | Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer |
| Q39659182 | Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer |
| Q37480868 | Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1. |
| Q96228528 | Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study |
| Q50942747 | Implementing a telephone based peer support intervention for women with a BRCA1/2 mutation. |
| Q43677630 | Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis |
| Q81481436 | Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software |
| Q35105959 | In their own words: treating very young BRCA1/2 mutation-positive women with care and caution |
| Q37507426 | Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study |
| Q43843055 | Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers |
| Q36603837 | Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature |
| Q36907261 | Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation |
| Q36613591 | Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers |
| Q46208714 | Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers |
| Q46070838 | Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic |
| Q72215864 | Increasing incidence of breast cancer in family with BRCA1 mutation |
| Q50774834 | Independent origin of 185delAG BRCA1 mutation in an Indian family. |
| Q64388665 | Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families |
| Q81425159 | Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland |
| Q33237559 | Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers |
| Q71021207 | Informed consent and BRCA1 mutation detection in archived breast tumor specimens |
| Q83962378 | Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer |
| Q91183709 | Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers |
| Q36168564 | International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers |
| Q93012417 | International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation |
| Q34116505 | International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers |
| Q40247920 | Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population. |
| Q98193682 | Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore |
| Q52338383 | Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers. |
| Q42474202 | Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers. |
| Q44565707 | Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? |
| Q86541616 | Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers? |
| Q85919404 | Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics |
| Q37662402 | Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature |
| Q83180389 | Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? |
| Q89848702 | Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up |
| Q77208085 | Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation |
| Q98626351 | LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS |
| Q46250003 | Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland |
| Q59271724 | Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland |
| Q37709882 | Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation |
| Q53509871 | Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. |
| Q33885464 | Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age. |
| Q48417408 | Lifestyle behaviors in women with a BRCA1 or BRCA2 genetic mutation: an exploratory study guided by concepts derived from the Health Belief Model. |
| Q37513545 | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study). |
| Q36394369 | Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases |
| Q46901108 | Living with the BRCA1 and BRCA2 genetic mutation: learning how to adapt to a virtual chronic illness |
| Q34114943 | Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy |
| Q103813134 | Locoregional treatments and ipsilateral breast cancer recurrence rates in BRCA1/2 mutation carriers |
| Q24802704 | Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) |
| Q45507609 | Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. |
| Q83223060 | Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening |
| Q94473101 | Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers |
| Q36727459 | Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2 |
| Q37583113 | Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status |
| Q51016879 | Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. |
| Q37688802 | Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers |
| Q40278641 | Longitudinal cancer risk management trajectories of BRCA1/2 mutation-positive reproductive-age women |
| Q51796120 | Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls. |
| Q62490486 | Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers |
| Q40903518 | Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens |
| Q46361479 | Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). |
| Q42467935 | Low-grade adenosquamous carcinoma of the breast--A case report with a BRCA1 germline mutation |
| Q57694501 | Lymphocyte radiosensitivity inBRCA1 andBRCA2 mutation carriers and implications for breast cancer susceptibility |
| Q34700093 | Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status |
| Q46703168 | Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency |
| Q87290141 | MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers |
| Q73574289 | Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer |
| Q81726152 | Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q51830222 | Male to female ratio among offspring of BRCA1 mutation carriers. |
| Q51820769 | Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q35076152 | Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer |
| Q40693860 | Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models |
| Q51066796 | Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study. |
| Q59238246 | Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study |
| Q50234190 | Management of Breast Cancer in BRCA1/2 Mutation Carriers. |
| Q97544395 | Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer |
| Q36849977 | Management updates for women with a BRCA1 or BRCA2 mutation |
| Q97430846 | Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier |
| Q125082260 | Medical genetics: advances in brief: Risks of cancer in BRCA1-mutation carriers |
| Q55076960 | Medical genetics: advances in brief: Risks of cancer in BRCA1-mutation carriers. |
| Q80196980 | Medullary carcinoma of breast with a novel germline mutation 1123T >G in exon 11 of BRCA1 |
| Q74129857 | Medullary carcinoma of the breast and BRCA1 mutation |
| Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
| Q82046106 | Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution |
| Q37090813 | Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers |
| Q46325284 | Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer |
| Q90219103 | Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients |
| Q74052300 | Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol |
| Q59538857 | MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors |
| Q33508232 | MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary |
| Q74221855 | Microglandular adenosis of the breast in a BRCA1 mutation carrier: radiological features |
| Q34625221 | Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis |
| Q101240567 | Misinterpretation of Hereditary Breast Cancer Risk and Its Association with Information Sharing Motives among Women at Low Likelihood of Carrying a BRCA1/2 Mutation |
| Q87529582 | Mislocalization of BRCA1-complex due to ABRAXAS Arg361Gln mutation |
| Q77783880 | Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center |
| Q42698804 | Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. |
| Q37362211 | Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers |
| Q28067154 | Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers |
| Q33845209 | Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis |
| Q73454717 | Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers |
| Q57306222 | Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families |
| Q34038170 | Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status |
| Q42455702 | Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. |
| Q53551079 | Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing. |
| Q93078895 | More Is More: Semiannual Breast MRI Screening in BRCA1 Mutation Carriers |
| Q35521562 | Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer |
| Q34498634 | Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study |
| Q40251990 | Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers |
| Q37525477 | Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation |
| Q89543296 | Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers |
| Q93067018 | Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms |
| Q62725095 | Multiple copies of mutantBRCA1 andBRCA2 alleles in breast tumors from germ-line mutation carriers |
| Q55243800 | Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers. |
| Q62583349 | Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells |
| Q53382180 | Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation. |
| Q64387889 | Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation |
| Q94022385 | Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers |
| Q57306016 | Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients |
| Q79353575 | Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer |
| Q81787605 | Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families |
| Q73038076 | Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer |
| Q35238410 | Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. |
| Q41734561 | Mutation analysis of BRCA1 gene in African-American patients with breast cancer. |
| Q34460831 | Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer |
| Q73474551 | Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors |
| Q55085561 | Mutation analysis of BRCA1/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients. |
| Q54460596 | Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. |
| Q54791507 | Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis. |
| Q34178875 | Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada |
| Q35889909 | Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families |
| Q64386822 | Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families |
| Q21343014 | Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G |
| Q49171044 | Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. |
| Q33677871 | Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites |
| Q48070015 | Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation |
| Q74630713 | Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients |
| Q41674947 | Mutation analysis of the BRCA1 gene in ovarian cancers. |
| Q54731209 | Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females. |
| Q59238320 | Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families |
| Q33922795 | Mutation detection in K-ras, BRCA1, BRCA2, and p53 using PCR/LDR and a universal DNA microarray. |
| Q73936250 | Mutation detection in the breast cancer gene BRCA1 using the protein truncation test |
| Q35984974 | Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study |
| Q98780542 | Mutation in Exon2 of BRCA1 Gene in Adult Bengali Bangladeshi Female Patients with Breast Cancer: An Experience from Two Tertiary-Care Hospitals |
| Q73205349 | Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript |
| Q90273490 | Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer |
| Q35470405 | Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells |
| Q34491545 | Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining |
| Q33891865 | Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population |
| Q58858704 | Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis |
| Q74582692 | Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases |
| Q55033531 | Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families. |
| Q41691570 | Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study |
| Q77929777 | Mutation screening of the BRCA1 gene in Slovak patients |
| Q36501516 | Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. |
| Q82208952 | Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations |
| Q33824592 | Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families |
| Q80093419 | Mutation screening using fluorescence multiplex denaturing gradient gel electrophoresis (FMD): detecting mutations in the BRCA1 gene |
| Q39395809 | Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia. |
| Q47141035 | Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations |
| Q33721323 | Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. |
| Q48842485 | NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. |
| Q38876050 | Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers |
| Q46250020 | Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment |
| Q71060920 | New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families |
| Q40449065 | New approaches to BRCA1 mutation detection. |
| Q92919853 | New recurring BRCA1 variant: An additional South African founder mutation? |
| Q82425722 | Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation |
| Q25257803 | Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation |
| Q49893879 | Nipple-sparing bilateral prophylactic mastectomy and immediate reconstruction with TiLoop® Bra mesh in BRCA1/2 mutation carriers: A prospective study of long-term and patient reported outcomes using the BREAST-Q. |
| Q38229437 | Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature |
| Q77420326 | No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report |
| Q42913943 | No association between MTHFR 677C>T polymorphism and ovarian cancer risk in BRCA1 mutation carriers in Wielkopolska region |
| Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
| Q60300119 | No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers |
| Q36610368 | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
| Q47154249 | No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families |
| Q51699099 | No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q78412111 | No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches |
| Q37331124 | No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers |
| Q102335087 | No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers |
| Q89975415 | Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control |
| Q59238453 | Nonovarian Pelvic Cancers in BRCA1/2 Mutation Carriers and the BRCAPRO Statistical Model |
| Q54960766 | Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients. |
| Q36927115 | Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies |
| Q51795327 | Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. |
| Q87451291 | Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry |
| Q36121590 | Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer |
| Q48163026 | Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin. |
| Q35862273 | Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma |
| Q44226465 | Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalenc |
| Q46353526 | Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer |
| Q28763558 | Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families |
| Q90360888 | Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers |
| Q51715899 | OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer. |
| Q34172655 | Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers |
| Q89777478 | Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial |
| Q90856051 | Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation |
| Q126659603 | Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort |
| Q103721769 | Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort |
| Q56240758 | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation |
| Q39933788 | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety |
| Q38654552 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q90184252 | Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation |
| Q39000667 | Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer |
| Q34434501 | One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding |
| Q35808372 | Online tool to guide decisions for BRCA1/2 mutation carriers |
| Q36671223 | Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q91524809 | Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers |
| Q85895919 | Oophorectomy benefits in breast cancer patients with BRCA1 mutation |
| Q36611675 | Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models |
| Q77158608 | Optimization of PCR and electrophoresis conditions enhances mutation analysis of the BRCA1 gene |
| Q37524764 | Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone |
| Q92281866 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
| Q30433319 | Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study |
| Q34162534 | Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q57961666 | Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1–2 mutation carriers |
| Q39715889 | Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells |
| Q46944402 | Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up. |
| Q39095660 | Out-RANKing BRCA1 in Mutation Carriers. |
| Q53408126 | Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. |
| Q37408259 | Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q92487225 | Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation |
| Q95852901 | Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation |
| Q98622406 | Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation: Correction |
| Q74826491 | Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP) |
| Q36983535 | Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. |
| Q41517608 | Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk |
| Q33327308 | Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q30883827 | Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. |
| Q89224654 | Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers |
| Q46944056 | P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers |
| Q36303235 | PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland |
| Q27027503 | PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies |
| Q34167479 | PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer |
| Q37668511 | PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |
| Q46752950 | PCR-free mutation detection of BRCA1 on a zip-code microarray using ligase chain reaction. |
| Q37316953 | PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers |
| Q79772653 | PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations |
| Q104574984 | Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report |
| Q50905992 | Parental Decision Making Regarding the Disclosure or Nondisclosure of a Mutation-Positive BRCA1/2 Test Result to Minors. |
| Q90041756 | Parental disclosure of positive BRCA1/2 mutation status to children 10 years after genetic testing |
| Q87445924 | Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation |
| Q35633640 | Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers |
| Q51644200 | Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. |
| Q34741387 | Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. |
| Q78688118 | Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers |
| Q42506787 | Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers |
| Q38460975 | Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q81596061 | Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation |
| Q38991209 | Peer support and additional information in group medical consultations (GMCs) for BRCA1/2 mutation carriers: A randomized controlled trial |
| Q54113081 | Penetrance of BRCA1 gene mutation and DNA mitochondrial in Tunisian breast cancer occurrence |
| Q97530605 | Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis |
| Q89871616 | Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention |
| Q37121713 | Performance of BRCA1/2 mutation prediction models in Asian Americans |
| Q38739022 | Performance of BRCA1/2 mutation prediction models in male breast cancer patients. |
| Q50859124 | Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers. |
| Q52822438 | Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. |
| Q47189965 | Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. |
| Q58601877 | Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies |
| Q33415400 | Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses |
| Q35671356 | Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 |
| Q82660651 | Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers? |
| Q48266858 | Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. |
| Q62978158 | Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers |
| Q50194011 | Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. |
| Q39553159 | Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study |
| Q60585018 | Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study |
| Q37699313 | Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q91582428 | Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation |
| Q45386947 | Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer |
| Q34618389 | Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies. |
| Q34780052 | Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q44116893 | Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada |
| Q51117836 | Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. |
| Q51574104 | Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers. |
| Q30432372 | Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. |
| Q33416772 | Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma |
| Q35167622 | Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation |
| Q35443103 | Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics |
| Q38723550 | Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries. |
| Q34102617 | Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models |
| Q34311315 | Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study |
| Q31152672 | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics |
| Q40216095 | Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability |
| Q43416110 | Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. |
| Q36173170 | Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype |
| Q61626208 | Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36541027 | Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations |
| Q35006900 | Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q46808117 | Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group |
| Q94562923 | Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis |
| Q53208810 | Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. |
| Q49787762 | Predictors of survival for breast cancer patients with a BRCA1 mutation. |
| Q100436825 | Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation |
| Q38669803 | Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment |
| Q80397130 | Pregnancy after in vitro fertilization-intracytoplasmic sperm injection obtained with a modified natural cycle in a BRCA1 mutation carrier |
| Q45218603 | Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers |
| Q80778880 | Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth |
| Q28245938 | Premature menopause in patients with BRCA1 gene mutation |
| Q39860034 | Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. |
| Q73966464 | Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation |
| Q74239116 | Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO |
| Q78378129 | Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO |
| Q54620289 | Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. |
| Q91503116 | Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea |
| Q34371756 | Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China. |
| Q45970196 | Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. |
| Q49061352 | Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. |
| Q126833887 | Prevalence of Germline Brca1 and Brca2 Mutation Among Filipinos |
| Q46576514 | Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups |
| Q81029166 | Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group |
| Q36936755 | Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country |
| Q35856408 | Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome |
| Q39314538 | Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers |
| Q34011730 | Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer |
| Q95499347 | Previving: How Unaffected Women with a BRCA1/2 Mutation Navigate Previvor Identity |
| Q53409844 | Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. |
| Q34100353 | Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation |
| Q80243586 | Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models |
| Q57266692 | Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families |
| Q52274948 | Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. |
| Q92462233 | Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer |
| Q43773289 | Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives |
| Q36633089 | Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review |
| Q88570200 | Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients |
| Q37388751 | Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer |
| Q43657320 | Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation |
| Q37390113 | Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. |
| Q54335422 | Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. |
| Q51692616 | Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. |
| Q86932123 | Promoter mutation and reduced expression of BRCA1 in canine mammary tumors |
| Q40449831 | Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. |
| Q35684391 | Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers |
| Q45021655 | Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis |
| Q44352161 | Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer |
| Q33286372 | Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic |
| Q42631142 | Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations |
| Q78454420 | Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers |
| Q34074423 | Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. |
| Q36634141 | Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. |
| Q79919779 | Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation |
| Q81517669 | Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation |
| Q87232422 | Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q95725188 | Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers |
| Q35930061 | Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence |
| Q36920323 | Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging |
| Q84785212 | Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families |
| Q35130901 | Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study' |
| Q93179267 | Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study |
| Q36614710 | Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype |
| Q87224311 | Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation? |
| Q38807460 | Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review |
| Q51066856 | Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. |
| Q51108082 | Psychological responses to BRCA1 mutation testing: preliminary findings. |
| Q38763072 | Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer |
| Q51874359 | Quality of life in asymptomatic BRCA1/2 mutation carriers. |
| Q91036877 | Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial |
| Q62725045 | Quantitative Analysis of γ-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers |
| Q35782790 | Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers |
| Q43434374 | RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies |
| Q39670403 | RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. |
| Q37457304 | RANKL/RANK control Brca1 mutation-driven mammary tumors |
| Q33708522 | RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers |
| Q52778014 | RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. |
| Q42873665 | RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction |
| Q78198692 | RESPONSE: Re: Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer |
| Q40443521 | Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis |
| Q36696594 | Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. |
| Q47797693 | Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for BRCA1/2 mutation carriers |
| Q33768504 | Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. |
| Q50612189 | Randomized controlled trial of a telephone-based peer-support program for women carrying a BRCA1 or BRCA2 mutation: impact on psychological distress. |
| Q36634289 | Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction |
| Q42633542 | Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers |
| Q51071605 | Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. |
| Q33923031 | Rates of BRCA1/2 mutation testing among young survivors of breast cancer |
| Q44657438 | Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers |
| Q53115341 | Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. |
| Q73600014 | Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q91252388 | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study |
| Q47284128 | Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis |
| Q98780552 | Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing |
| Q38457675 | Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population |
| Q44717730 | Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history |
| Q37185660 | Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific |
| Q43199387 | Reduced DNA repair in BRCA1 mutation carriers undetectable before onset of breast cancer? |
| Q62712486 | Redundant designations of BRCA1 intron 11 splicing mutation; c. 4216-2A>G; IVS11-2A>G; L78833, 37698, A>G |
| Q74297826 | Redundant designations of BRCA1 intron 11 splicing mutation; c. 4216-2A>G; IVS11-2A>G; L78833, 37698, A>G |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q41048340 | Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation |
| Q24810584 | Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families |
| Q34719906 | Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study |
| Q51245901 | Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. |
| Q51857808 | Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers. |
| Q84444594 | Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy |
| Q36640129 | Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies. |
| Q94340441 | Reply: Reduced DNA repair in BRCA1 mutation carriers undetectable before onset of breast cancer? |
| Q51488968 | Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families. |
| Q36901615 | Reproductive Endocrinologists' Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers. |
| Q44884896 | Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study |
| Q54448562 | Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies. |
| Q47658870 | Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). |
| Q30432062 | Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study |
| Q92729458 | Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies |
| Q93357160 | Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers |
| Q51188805 | Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies. |
| Q91558042 | Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel |
| Q83164988 | Retinal dysfunction in eyes of patients with BRCA1 gene mutation |
| Q37129828 | Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study |
| Q77706008 | Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posed |
| Q56928436 | Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families |
| Q54645721 | Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. |
| Q81023501 | Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing |
| Q57306230 | Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland) |
| Q91982210 | Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis |
| Q30426599 | Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status |
| Q41517367 | Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis |
| Q51208435 | Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. |
| Q51157118 | Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. |
| Q92517249 | Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China |
| Q38627833 | Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers |
| Q39217504 | Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers |
| Q51794096 | Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. |
| Q36615112 | Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers |
| Q90303597 | Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion |
| Q57908414 | Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation |
| Q45713505 | Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing |
| Q39064164 | Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives |
| Q84129294 | Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers |
| Q34129784 | Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation |
| Q92708085 | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers |
| Q91540326 | Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice? |
| Q45750405 | Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral |
| Q50787592 | Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. |
| Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
| Q79273436 | Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred |
| Q34724404 | Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium |
| Q55561905 | Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. |
| Q41129150 | Role of BRCA1 mutation screening in the management of familial ovarian cancer |
| Q57281310 | Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives |
| Q41990672 | Roles of DNA mutation in the coding region and DNA methylation in the 5' flanking region of BRCA1 in canine mammary tumors |
| Q64951832 | SUN-010 BRCA1 Mutation Influences Progesterone Response in Human Benign Mammospheres. |
| Q90613880 | Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile? |
| Q50854923 | Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk. |
| Q55042194 | Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. |
| Q36667134 | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
| Q60923372 | Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer |
| Q33923799 | Screening and clinical implications for BRCA1 and BRCA2 mutation carriers |
| Q22000758 | Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals |
| Q53256330 | Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. |
| Q55176423 | Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. |
| Q35983751 | Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry |
| Q34069150 | Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation |
| Q37330009 | Selected aspects of genetic counselling for BRCA1 mutation carriers |
| Q46738357 | Selenium and genotypes as marker of risk in BRCA1 mutation carriers |
| Q47757918 | Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers |
| Q35443794 | Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families |
| Q33476082 | Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q102979495 | Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status |
| Q39212515 | Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation |
| Q82637915 | Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen |
| Q46332902 | Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers. |
| Q59270668 | Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers |
| Q36691778 | Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review |
| Q47561619 | Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation |
| Q84088318 | Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers |
| Q41600086 | Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation? |
| Q44732177 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? |
| Q42642546 | Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring |
| Q88004070 | Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers? |
| Q40173313 | Should we screen BRCA1 mutation carriers only with MRI? A multicenter study |
| Q92574272 | Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis |
| Q35163789 | Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers |
| Q92076923 | Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma |
| Q38294122 | Skin cancer risk in BRCA1/2 mutation carriers |
| Q100432715 | Sleep and Circadian Rhythm Disruption Is Corrected by Lithium in a Case of Bipolar Disorder with Familial BRCA1 Mutation |
| Q48365317 | Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer |
| Q80647011 | Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy |
| Q37687527 | Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. |
| Q40226987 | Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation |
| Q48840957 | Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. |
| Q43197215 | Stemming the tide of cancer for BRCA1/2 mutation carriers |
| Q50701748 | Stigmatization and male identity: Norwegian males' experience after identification as BRCA1/2 mutation carriers. |
| Q53634735 | Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. |
| Q78125794 | Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online |
| Q27639943 | Structural consequences of a cancer-causing BRCA1-BRCT missense mutation |
| Q41035840 | Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report |
| Q85524680 | Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent |
| Q34663394 | Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis |
| Q44148124 | Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers |
| Q50748795 | Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. |
| Q40478270 | Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. |
| Q57250747 | Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers |
| Q60685218 | Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers |
| Q91858202 | Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers |
| Q24654487 | Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers |
| Q47220772 | Survival and recurrence after breast cancer in BRCA1/2 mutation carriers |
| Q51276495 | Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). |
| Q37182133 | Survival in Norwegian BRCA1 mutation carriers with breast cancer |
| Q31685836 | Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact. |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q34512590 | Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group |
| Q37129654 | Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers |
| Q44674115 | Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians |
| Q33927384 | Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study |
| Q37529386 | Telomere length shows no association with BRCA1 and BRCA2 mutation status |
| Q57194461 | Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing |
| Q38892074 | The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim |
| Q80187795 | The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon |
| Q44306036 | The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation |
| Q54503913 | The 4154delA mutation carriers in the BRCA1 gene share a common ancestry. |
| Q57250694 | The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q83266783 | The BRCA Self-Concept Scale: a new instrument to measure self-concept in BRCA1/2 mutation carriers |
| Q45768293 | The BRCA1 S1715N mutation segregates with breast and ovarian cancer in an extended family pedigree. |
| Q51551407 | The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. |
| Q33313283 | The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation |
| Q33675997 | The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q59601956 | The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers |
| Q56438043 | The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations |
| Q93358553 | The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers |
| Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q34800968 | The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers |
| Q40489662 | The Quality of Genetic Counseling and Connected Factors as Evaluated by Male BRCA1/2 Mutation Carriers in Finland |
| Q33949266 | The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript |
| Q79776026 | The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers |
| Q28207617 | The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation |
| Q47563569 | The Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers without a First-Degree Relative with Breast Cancer |
| Q38842957 | The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation |
| Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q56508883 | The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients |
| Q56508831 | The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews |
| Q55117795 | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study. |
| Q24797305 | The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q52684293 | The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position? |
| Q47560912 | The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers |
| Q32076900 | The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain |
| Q34294785 | The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals |
| Q37845179 | The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling |
| Q22252596 | The clinical management of BRCA1 and BRCA2 mutation carriers |
| Q50787652 | The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls. |
| Q57266710 | The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49 |
| Q51062456 | The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers. |
| Q33962070 | The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q102155578 | The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer? |
| Q34141842 | The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group |
| Q37185593 | The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy. |
| Q46301352 | The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers |
| Q36161162 | The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine |
| Q25257213 | The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations |
| Q36717832 | The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety |
| Q83760986 | The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer |
| Q37613551 | The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation |
| Q43073845 | The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation |
| Q50955163 | The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. |
| Q89480991 | The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy |
| Q89718319 | The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study |
| Q36451732 | The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers |
| Q51835514 | The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. |
| Q75198589 | The novel exon 11 mutation of BRCA1 gene in a high-risk family |
| Q37332573 | The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers |
| Q42368096 | The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation |
| Q73742292 | The predictive value of BRCA1 and BRCA2 mutation testing |
| Q48154043 | The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers |
| Q104470951 | The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies |
| Q35907001 | The risk of breast cancer in women with a BRCA1 mutation from North America and Poland |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q35691859 | The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future |
| Q34683768 | The role of p53 mutation in BRCA1-associated ovarian cancer. |
| Q51075493 | The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. |
| Q45904532 | The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q81340126 | The sensitivity of BRCA1 mutation carriers to ionising radiation: questions of methodology |
| Q47629752 | The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers. |
| Q46542512 | The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation |
| Q34108442 | The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation |
| Q59482573 | Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases |
| Q74195675 | Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier |
| Q33277125 | Time to decide about risk-reducing mastectomy: a case series of BRCA1/2 gene mutation carriers |
| Q51125402 | Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? |
| Q100402239 | Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers |
| Q44256039 | Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q51592828 | Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. |
| Q79772751 | Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers |
| Q51887153 | Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers. |
| Q47397232 | Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach |
| Q35916613 | Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy |
| Q74549034 | Transitional cell ovarian carcinoma in a BRCA1 mutation carrier |
| Q78008472 | Transitional cell ovarian carcinoma in a BRCA1 mutation carrier |
| Q46801017 | Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation |
| Q104757525 | Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation |
| Q86101689 | Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report |
| Q36896061 | Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers |
| Q46354502 | Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance |
| Q35050560 | Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations |
| Q95816905 | Tumor-specific therapy based on BRCA1/2 mutation status |
| Q35109897 | Tumorigenesis in mice carrying a truncating Brca1 mutation |
| Q35882682 | Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds |
| Q38464687 | Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome |
| Q99628476 | Ultrasensitive colorimetric biosensor for BRCA1 mutation based on multiple signal amplification strategy |
| Q35480489 | Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China |
| Q36925152 | Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study |
| Q48554849 | Unmet support needs and distress among women with a BRCA1/2 mutation. |
| Q37996438 | Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers |
| Q34351382 | Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers |
| Q75397290 | Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway |
| Q98300195 | Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation |
| Q88956222 | Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers |
| Q91648248 | Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France |
| Q35879809 | Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women |
| Q33533295 | Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. |
| Q54775737 | Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation |
| Q34751856 | Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q28261738 | Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers |
| Q97907314 | Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review |
| Q37148659 | Use of gene expression profiles of peripheral blood lymphocytes to distinguish BRCA1 mutation carriers in high risk breast cancer families. |
| Q34475484 | Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers |
| Q46755164 | Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy |
| Q39672610 | Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers |
| Q93390874 | Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers |
| Q37574065 | Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1 |
| Q81638935 | Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients |
| Q35983873 | Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation |
| Q35609850 | Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing |
| Q36001486 | Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families |
| Q37412593 | Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer |
| Q37901952 | Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers |
| Q48535403 | Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. |
| Q77857319 | Variation in BRCA1 cancer risks by mutation position |
| Q36924486 | Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). |
| Q28386156 | Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q84562970 | Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO) |
| Q33572852 | Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. |
| Q81170030 | Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients |
| Q38840468 | Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. |
| Q38638531 | Vitamin D Receptor Gene Polymorphism: Association with Susceptibility to Early-Onset Breast Cancer in Iranian, BRCA1/2-Mutation Carrier and non-carrier Patients |
| Q74741429 | Voluntary disclosure of BRCA1 mutation test results |
| Q40641271 | Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation |
| Q52092768 | What about prophylactic surgery in BRCA1/BRCA2 mutation carriers? Observations from an Italian pilot study. |
| Q46590884 | What are the unmet support needs of women with a known BRCA1/2 mutation? |
| Q36583892 | When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans. |
| Q47101331 | When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges. |
| Q104484001 | Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer |
| Q39815278 | Women receiving news of a family BRCA1/2 mutation: messages of fear and empowerment. |
| Q35224593 | Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis |
| Q73469369 | Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer |
| Q47586232 | Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. |
| Q51832387 | Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. |
| Q80752304 | [5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients] |
| Q83813902 | [An immunohistochemical study of aromatase, estrogen 4-hydroxylase and fatty acid synthetase in breast cancer tissues from BRCA1 mutation carriers] |
| Q64388031 | [Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer] |
| Q64387721 | [Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer] |
| Q80448798 | [Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang] |
| Q88385198 | [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer] |
| Q80119977 | [BRCA1 1100delAT is a recurrent mutation in Chinese women with familial breast cancer] |
| Q80390244 | [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer] |
| Q53089790 | [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer]. |
| Q82993123 | [BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases] |
| Q52957764 | [Breast cancer in BRCA1/2 mutation carriers]. |
| Q89257696 | [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis] |
| Q90660155 | [Cost-effectiveness of risk-reducing salpingo-oophorectomy in cases of BRCA1 gene mutation in Colombia] |
| Q54445586 | [Detection of 5382insC mutation in human BRCA1 gene using fluorescent labeled oligonucleotides] |
| Q83675791 | [Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part I: evaluation of stomatognathic system in youth BRCA1 gene mutation carriers] |
| Q83675796 | [Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy] |
| Q73409181 | [Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France] |
| Q81029752 | [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method] |
| Q53647699 | [Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers]. |
| Q86042691 | [Having a child and PND/PGD access in women with a BRCA1/2 mutation? Different approach whether ill or healthy] |
| Q81318220 | [Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives] |
| Q54539542 | [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases]. |
| Q52123487 | [Mutation BRCA1 gene in 186 breast cancer patients] |
| Q81694140 | [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer] |
| Q84235482 | [Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors] |
| Q79804564 | [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation] |
| Q83975084 | [Relationship between mutation of BRCA1 and susceptibility to early onset of breast cancer] |
| Q53144751 | [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer]. |
| Q83558613 | [Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation] |
| Q83692191 | [What management for the asymptomatic men carriers of BRCA1 or 2 mutation? Results of a survey in the French oncogenetic centers] |
| Q42808096 | c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. |
| Q36544789 | miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers |
| Q89842473 | miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil |
| Q77491932 | p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours |
| Q58694347 | Survivial Outcomes in BRCA1 or BRCA2 Mutation Carriers and the Influence of Triple-Negative Breast Cancer Subtype |
Search more.